Sept 29 (Reuters) - AbbVie ( ABBV ) said on Monday it

would launch its ovarian cancer drug Elahere in the UK at a list

price matching that in the U.S.

President Donald Trump has been demanding that drugmakers

align domestic prices with the lowest levels paid by comparable

high-income countries under the "most-favored-nation" policy.

The U.S. pays nearly three times more for prescription drugs

compared to other developed nations.

Last week, Bristol Myers Squibb said it planned to

launch schizophrenia drug Cobenfy in the UK next year at a price

matching its U.S. list price.

AbbVie ( ABBV ) was one of the 17 drugmakers to receive letters from

U.S. President Donald Trump in July outlining how they should

cut prices to match those paid overseas.

The company was in discussions with Britain's

cost-effectiveness watchdog, National Institute for Health and

Care Excellence, to ensure the drug is valued fairly, the

drugmaker said on Monday.

AbbVie ( ABBV ) said the talks will determine Elahere's launch in the

UK. The company did not immediately respond to a request on the

pricing.

Unlike in the U.S., where market forces determine drug

prices, European governments typically negotiate directly with

companies to set prices for their national healthcare systems.

Elahere, available in the U.S. since 2022, belongs to a new

class of treatments called antibody-drug conjugates, or "guided

missile" drugs, that precisely target cancer cells, potentially

reducing toxicity for other cells.

(Reporting by Mariam Sunny in Bengaluru; Editing by Leroy Leo

and Sriraj Kalluvila)